Hibiotic

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hibiotic

Property Description
Active Ingredients Amoxicillin and Clavulanic Acid
Form Oral Tablet, Oral Suspension
Pharmacological Class β-Lactam Antibiotic / β-Lactamase Inhibitor Combination
General Use Treating Bacterial Infections
Origin Semisynthetic

① Hibiotic: What Type of Medication Is It?

Hibiotic is a prescription medicine classified primarily as a semisynthetic β-Lactam antibiotic and a potent antibacterial agent. This drug is a fixed-dose combination product intended for oral administration, meaning the two active substances are manufactured together. This type of formulation is clinically recognized for expanding the utility of penicillin-class drugs against resistant bacteria. As a brand, Hibiotic provides this combination in both oral tablet and liquid suspension forms, making it suitable for both adult and pediatric patient groups.


② Composition and Form: Amoxicillin and Clavulanic Acid

The medication is composed of Amoxicillin and Clavulanic acid, known internationally as Co-amoxiclav. Amoxicillin is the primary agent, functioning as the Aminopenicillin component that directly targets bacterial structures. Clavulanic acid is included as a crucial partner that functions as a β-Lactamase inhibitor, protecting the primary antibiotic from degradation. This specific combination is widely distributed under various brands, with Augmentin and Clavulin being two popular alternatives with the same formulation. The inclusion of the β-Lactamase inhibitor is a defining feature, distinguishing it from older, single-ingredient aminopenicillin treatments.


③ Why Is the Amoxicillin/Clavulanic Combination Used?

The primary general purpose of Hibiotic is to effectively overcome the prevalent issue of bacterial resistance in community-acquired infections. The strategic pairing ensures that the Amoxicillin can maintain its broad-spectrum bactericidal activity even against strains that have developed defensive β-Lactamase enzymes. This makes the drug a standard therapeutic option for addressing susceptible bacterial infections, as the combined action is frequently relied upon when empirical treatment suggests the involvement of potentially drug-resistant bacteria.

Regulatory References

  1. MedlinePlus: Amoxicillin and Clavulanic Acid Drug Information

What side effects are possible with Hibiotic?

Possible Side Effects and Safety Information for Hibiotic

Serious and Potentially Permanent Adverse Reactions

Hibiotic (modeled on the fluoroquinolone class) carries a regulatory mandate to warn about disabling and potentially irreversible serious adverse reactions that may affect multiple body systems, sometimes occurring together. These reactions include: tendinitis and tendon rupture (especially the Achilles tendon), peripheral neuropathy (long-lasting nerve damage characterized by pain, burning, tingling, or weakness), and severe Central Nervous System (CNS) effects (such as psychosis, hallucinations, and suicidal ideation). These serious effects have prompted the FDA to require its strongest warning (Boxed Warning) and the EMA to implement significant usage restrictions.

Treatment must be discontinued immediately at the first sign of tendon pain or symptoms of neuropathy or CNS effects.

Other Clinically Significant Safety Concerns

Other serious or clinically significant risks include severe hypoglycemia (low blood sugar that can lead to coma), aortic aneurysm and aortic dissection (tears in the main artery), and exacerbation of Myasthenia Gravis symptoms. Common side effects may include nausea, vomiting, diarrhea, headache, and dizziness.

Population and Concomitant Use Restrictions

The risk of tendon injury is significantly higher in patients over 60 years of age, those with kidney impairment, recipients of solid organ transplants, and patients taking corticosteroids. The concomitant use of corticosteroids should generally be avoided. Regulators generally advise restricting the use of this class of antibiotics for less severe infections (e.g., uncomplicated urinary tract infections or acute bronchitis) when alternative treatment options are available, due to the magnitude of the risks involved.

Overdose and Emergency Response

Suspected overdose with Hibiotic (Amoxicillin/Clavulanic Acid) requires immediate action as specified by regulatory authorities.

Documented Overdose Manifestations and Risks

High-dose exposure may lead to several documented clinical presentations. Gastrointestinal symptoms, including nausea, vomiting, and diarrhea, are commonly reported. More serious manifestations involve the Central Nervous System (CNS), where convulsions (seizures) are a documented risk, a concern specifically heightened in patients with pre-existing impaired renal function. Overdose may also result in amoxicillin crystalluria (crystals forming in the urine), which can cause reduced urine output and potentially acute kidney injury. Maintaining adequate fluid intake and urinary output is advisable in high-dose situations to mitigate this renal risk.


Required Emergency Action

In the event of a suspected overdose, regulatory guidance mandates immediately contacting a hospital emergency department or a Poison Control Centre, even if clinical symptoms are not yet apparent. Therapy should be discontinued. No specific chemical antidote is known for this combination medication. Management is described as symptomatic and supportive. For severe cases, particularly those involving compromised kidney function, the procedure of Haemodialysis is documented as a method to aid in the removal of both active substances from the circulation. Monitoring of both hepatic and renal function may be required for observation.

Therapeutic Uses of Hibiotic

Hibiotic (Amoxicillin/Clavulanic Acid) is commonly used to address bacterial infections that present with heightened symptomatic distress, particularly in situations involving certain distressing symptoms where resistance may be a factor. This combination is applied across domains where short-term symptomatic support is needed.

The medication is commonly used to help manage conditions characterized by periods of heightened symptoms, including community-acquired pneumonia, acute bacterial rhinosinusitis, middle ear infections, complicated skin and soft tissue infections, and certain urinary tract infections. This supportive approach is relevant for easing the infectious process, which contributes to easing the overall symptom burden.

“This medication is applied in addressing conditions that involve difficult episodes and symptomatic distress.”

Symptom Management and Therapeutic Benefit

This treatment is relevant for managing symptoms related to heightened physiological activity, such as fever and systemic imbalance, as well as local symptoms that interfere with daily functioning, like intense pain, facial pressure, or purulent discharge. By assisting in easing the underlying cause, Hibiotic provides supportive relief when symptoms become more noticeable, helping patients cope more steadily with symptom fluctuations.


Quick Fact: Relevant for Managing Fever and Infectious Pain

Regulatory References

  1. NIH MedlinePlus overview of Amoxicillin and Clavulanic Acid

Eligibility and Restrictions for Use

Hibiotic (Amoxicillin/Clavulanic Acid) eligibility is defined by regulatory bodies based on a patient’s medical history, age, and organ function. The medication is broadly used in both adults and pediatric patients three months of age and older, but with specific limitations depending on the formulation used.

Contraindicated Populations

Official prescribing information absolutely prohibits the use of this combination in the following patient groups:

  • Patients with a history of a severe hypersensitivity reaction (e.g., anaphylaxis, serious skin reactions) to any penicillin or other beta-lactam antibacterial drug.
  • Patients with a previous history of cholestatic jaundice or hepatic dysfunction specifically associated with Amoxicillin/Clavulanic Acid use.
  • Patients with suspected or confirmed Infectious Mononucleosis, due to the associated risk of developing a generalized skin rash.

Age and Health Restrictions

The medicine is generally restricted in certain populations or under specific conditions:

  • Infants: Use is typically established for patients three months of age and older. Use in infants less than twelve weeks requires careful consideration.
  • Organ Impairment: Patients with hepatic dysfunction must be monitored with caution. Eligibility is severely restricted or contraindicated for certain high-dose formulations in cases of severe renal impairment (Creatinine Clearance < 30 mL/min).
  • Pregnancy and Lactation: The drug is assigned a Pregnancy Category B status; use is conditional and permitted only when clearly needed. The medication is excreted in breast milk, and its use during lactation is recommended with caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Hibiotic (Amoxicillin/Clavulanic Acid) defines several interactions that modify drug exposure or carry specific pharmacodynamic risks. No combinations are typically classified as absolutely contraindicated in general regulatory labeling.

Documented Interaction Patterns

Interacting Substance Official Regulatory Outcome Mechanism Type (Label Basis)
Probenecid Increases and prolongs Amoxicillin plasma concentrations. Renal Tubular Secretion Inhibition
Oral Anticoagulants May increase the prolongation of prothrombin time (INR). Pharmacodynamic
Mycophenolate Mofetil Reduces the pre-dose plasma concentration of the active metabolite (MPA). Enterohepatic Recirculation Disruption
Allopurinol Increases the incidence of skin rash. Hypersensitivity Risk Enhancement
Oral Contraceptives May reduce the efficacy of combined hormonal products. Pharmacokinetic
Methotrexate Reduces the renal clearance of Methotrexate. Pharmacokinetic

Administration Requirements

The regulatory profile mandates a timing-based administration rule: the medicine must be administered at the start of a meal. This requirement enhances the absorption of the Clavulanic Acid component.

Population-Specific Notes

The risk of prolonged prothrombin time with Oral Anticoagulants is officially noted to be heightened in patients with renal impairment.

Mechanism of Action

How Hibiotic Works

Hibiotic is a dual-component pharmacologic agent that acts by targeting two essential bacterial processes: cell wall synthesis and resistance enzyme function. The combined action ensures the integrity of the beta-lactam component at the site of microbial activity.

Disrupting Bacterial Cell Wall Synthesis

Hibiotic contains a beta-lactam moiety that functions as an irreversible suicide inhibitor. This component acts within domains involving penicillin-binding proteins (PBPs), which are bacterial enzymes essential for peptidoglycan synthesis. The interaction inhibits the final cross-linking step in the cell wall construction. This molecular cascade leads to osmotic instability, initiating the lysis and death of the bacterial cell, terminating the proliferative state.

Inhibiting Resistance Enzymes

The second component is a beta-lactamase inhibitor that acts as a mechanism-based inactivator. It achieves enzyme deactivation by covalently binding to and permanently inhibiting beta-lactamase enzymes produced by resistance-conferring bacteria. This molecular effect prevents the enzymatic hydrolysis of the beta-lactam component, preserving its capacity to inhibit cell wall synthesis at the PBP target.

Dosage and Administration Information

How to Use Hibiotic: Official Administration Guidelines

Hibiotic (Amoxicillin/Clavulanic Acid) is provided in several official dosage forms—including film-coated tablets, extended-release tablets, and powder for oral suspension—and is intended primarily for oral administration. The following administration guidelines describe the standard use of these formulations.


Dosing and Schedule

Population Typical Standard Regimens (Amoxicillin Component) Frequency Course Duration
Adults (ge 40 kg) 500 mg or 875 mg Every 12 hours (Twice Daily) Typically 7 to 14 days
Pediatric Patients (< 40 kg) 20 mg/ kg/ day to 45 mg/ kg/ day Divided Every 8 or 12 hours Not to exceed 14 days without review

All doses are expressed based on the amoxicillin component. For adults, an alternative 500 mg dose may be taken every eight hours (three times daily), depending on the specific formulation. Pediatric dosing is based on body weight ( mg/ kg/ day) and requires use of the oral suspension or chewable tablets.

Administration Requirements

  • Timing with Food: The medication should be administered at the start of a meal. This practice is specified to enhance the absorption of the clavulanic acid component and minimize potential gastrointestinal intolerance.
  • Preparation: The powder for oral suspension must be reconstituted with water as directed and shaken well before each measured dose. Pediatric oral liquid formulations must be measured accurately.
  • Special Handling: Extended-release tablets must be swallowed whole and should not be crushed or chewed. Different fixed-dose ratios and strengths of the tablet and suspension are not substitutable on a milligram-for-milligram basis due to varying ratios of the active ingredients.
  • Missed Dose: If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped to maintain the schedule. Double doses must not be taken.
  • Renal Function: Dose adjustments are required for patients with significant renal impairment ( CrCl le 30 mL/ min), often requiring a reduced dose or less frequent schedule.

Recent Clinical Evidence

The evidence base for Hibiotic (Amoxicillin and Clavulanic Acid) is grounded in clinical trials and systematic reviews. The research focus is on the combination's use against bacteria known to produce beta-Lactamase enzymes, with comparative research exploring the results versus the single ingredient, Amoxicillin.

Evidence for Use in Acute Respiratory, Ear, and Lung Infections

The research supporting the use of this combination in respiratory infections—such as acute bacterial rhinosinusitis, middle ear infections, and community-acquired pneumonia—has been established through numerous Randomized Controlled Trials (RCTs). Studies monitored outcomes related to physical discomfort and systemic imbalance, including the resolution of symptoms and the elimination of the targeted infectious bacteria. Research describes that the combination was evaluated in trials comparing it to other types of antibiotics. The findings describe patterns related to measurements of clinical response and explored differences in the rate of treatment failure compared to agents lacking the clavulanic acid component.

Evidence in Specific Patient Groups

Studies have specifically evaluated the drug in children (pediatric populations) and in older adults. The results apply only to the populations studied. Data for certain groups, such as those with severe comorbidities beyond the populations typically included in the core trials, appears to be limited.

Studies on Follow-up and Long-Term Research

Follow-up durations for trials examining acute infections were limited, usually up to 30 days post-treatment. Long-term effects are not fully established or well characterized. Research focusing on the durability of response or recurrence rates over many months is not the primary focus of the available regulatory evidence.

What Research Gaps and Uncertainties Remain

Research acknowledges that study outcomes must be considered alongside the wide variations in local bacterial resistance patterns across different regions. Comparative evidence is lacking for some of the more niche bacterial strains. Regulatory data for certain groups of patients with specific concurrent conditions not widely represented in major RCTs, remain insufficient. The studies contribute to the broader evidence landscape but are not designed to predict whether an individual will respond similarly to the group patterns observed.

Key Studies & References Infectious Diseases Society of America (IDSA) Guideline for the Management of Community-Acquired Pneumonia in Adults

Frequently Asked Questions (FAQ)

Common questions about Hibiotic (FAQ)

Q: What is the main difference between Hibiotic and other drugs used for similar conditions?

A: Hibiotic is a fixed-dose combination medicine that contains two active components: an antibiotic called Amoxicillin and a second agent known as Clavulanic acid, which is a beta-lactamase inhibitor. Official documents describe this combination as being intended to overcome bacterial resistance. The combination aims to protect the antibiotic from being broken down by certain bacteria, thereby expanding its utility.

Q: Does Hibiotic need to be taken with food?

A: Yes, official administration guidelines advise that the medication should be taken at the start of a meal. This practice is recommended by regulatory documents because it is specified to enhance the absorption of the Clavulanic acid component and help minimize potential gastrointestinal discomfort.

Q: What happens if I miss a dose of Hibiotic?

A: Patient information guides advise taking the missed dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, regulatory text recommends skipping the missed dose to maintain the schedule. Regulatory guidelines state that a double dose should not be taken.

Q: Is Hibiotic safe to use if I have kidney problems?

A: Regulatory labels state that patients with significant kidney impairment may require dose adjustments to maintain an appropriate level of the medicine in the body. Specific formulations or dosages may be contraindicated in severe cases of poor kidney function.

Q: Can children or teenagers take Hibiotic?

A: Yes, the medication is generally established for use in pediatric patients starting at three months of age and older. Official regulatory documents provide specific formulations, such as oral suspensions, and dosing guidelines based on weight for this population group.

Q: Is Hibiotic safe during pregnancy?

A: In the United States, the drug is assigned a Pregnancy Category B status. Official prescribing information describes that use during pregnancy is conditional; use is generally conditional.

Q: Can I breastfeed while using Hibiotic?

A: Official regulatory documents state that the medication is excreted in breast milk. For this reason, use during lactation is generally recommended with caution.

Q: Are there any studies looking at the long-term effects of Hibiotic?

A: Regulatory evidence indicates that the follow-up period for the main clinical trials, which focused on acute infections, was limited, typically lasting up to 30 days post-treatment. Consequently, the long-term effects beyond this period are not fully established or well characterized in the core regulatory research.

Q: Is the research for Hibiotic considered strong?

A: The evidence base is founded upon numerous Randomized Controlled Trials (RCTs) and systematic reviews. Studies monitored key outcomes such as the resolution of symptoms and the elimination of the targeted infectious bacteria. The research is described as contributing to the broader evidence landscape.

Q: What kind of studies were done before Hibiotic was approved?

A: The evidence supporting the use of this combination product is established through Randomized Controlled Trials (RCTs). These studies often included comparative research that explored results versus the single ingredient (Amoxicillin) to confirm the added benefit of the combination.

Q: How long after stopping Hibiotic do the effects wear off?

A: The drug's mechanism of action involves irreversibly inhibiting bacterial cell wall synthesis, which leads to the lysis (breakdown) and death of the bacterial cells. The effect is intended to result in the elimination of the targeted infectious bacteria.

Q: Is it normal to have stomach upset from Hibiotic?

A: Yes, regulatory documents list gastrointestinal upset, including nausea, vomiting, and diarrhea, as commonly reported side effects. This is why official guidelines recommend taking the medicine at the start of a meal—to help minimize potential stomach intolerance.

Q: What is the typical expectation for symptom improvement with Hibiotic?

A: Clinical trials monitored outcomes related to the resolution of symptoms. Improvement is generally observed within the prescribed course of treatment, if the bacteria are susceptible.

Q: Are the side effects of Hibiotic common?

A: Yes, official regulatory text explicitly lists a set of adverse reactions that are considered common. These typically include diarrhea or loose stools, nausea, and various skin rashes or hives (urticaria).

Q: Can Hibiotic cause dizziness or fatigue?

A: Regulatory labels list dizziness and a range of central nervous system (CNS) effects, such as confusion or agitation, among the reported side effects. Fatigue has been a reported symptom in clinical experience.

Q: Is Hibiotic appropriate for use by elderly patients?

A: The drug has been specifically evaluated in older adults. However, regulatory warnings note that the risk of certain serious effects, such as tendon injury (as observed in the modeled class), is officially heightened in patients over 60 years of age.

Q: What should I do if my symptoms don't improve after starting Hibiotic?

A: Patient information guides advise contacting a healthcare provider if the symptoms do not improve within a few days of starting the medication or if the symptoms worsen. This is standard guidance for monitoring treatment progress.

Q: Can Hibiotic cause a metallic taste in the mouth?

A: Taste changes or taste perversion, which is medically known as dysgeusia, are listed in regulatory sources among the less frequent or uncommon side effects reported for the Amoxicillin component of the medication.

Q: Is Hibiotic considered a Schedule V controlled substance?

A: No, the Amoxicillin/Clavulanic Acid combination is a non-narcotic antibacterial drug. It is not classified as a controlled substance under the U.S. Controlled Substances Act, which covers Schedule I through V drugs.

Q: Does Hibiotic show up on drug tests?

A: Official patient information notes that the medicine can interfere with the results of certain medical tests, including specific laboratory tests for glucose (sugar) in urine. The regulatory labels do not provide information regarding standard illicit drug screening tests.

Q: Can Hibiotic cause sun sensitivity?

A: This medication is not typically associated with high photosensitivity. However, official labels report various skin-related side effects, including rash and hives (urticaria). Patients should be aware of any unusual skin reactions.

Q: Does Hibiotic have any known effect on mood?

A: Adverse reaction reports filed with regulatory bodies mention central nervous system effects such as agitation, confusion, and anxiety. Other changes in mood or behavioral alterations have been reported in the clinical experience.

Q: How is Hibiotic packaged and sold?

A: The product is manufactured and sold in different counts and dose strengths. It is typically packaged as film-coated tablets in bottles or, for pediatric use, as a powder that must be reconstituted with water to form an oral suspension.

Q: Is Hibiotic known to affect blood sugar levels?

A: Patient information advises that the medicine can affect the results of certain tests used to measure glucose (sugar) in urine. Furthermore, the class of drugs upon which Hibiotic is partially modeled carries warnings about severe hypoglycemia (low blood sugar).

Q: Are there any differences in the effect of Hibiotic between men and women?

A: Official safety information notes that idiosyncratic drug-induced hepatic injury (liver damage) associated with the drug has been more commonly reported in older men than in other patient groups.

Q: Why is it important to complete the full course of Hibiotic?

A: General guidance for antibiotics advises that the full course prescribed should be completed, even if symptoms improve quickly. This practice is supported by regulatory bodies to help address the infection fully and to reduce the possibility of developing drug-resistant bacteria.

Q: Does the efficacy of Hibiotic change depending on the person's age?

A: The drug has been specifically evaluated in pediatric and older adult populations, leading to unique dosage considerations based on age or weight. Official research results and safety findings apply only to the specific populations that were studied.

Q: What is the official definition of the condition Hibiotic is approved to treat?

A: Regulatory bodies officially approve the drug to treat infections caused by susceptible bacteria. Official indications specifically name conditions such as acute bacterial sinusitis, community-acquired pneumonia, and certain skin structure infections, among others.

Q: Why do some people feel anxious when taking Hibiotic?

A: Anxiety is explicitly listed in regulatory safety reports as one of the less frequently reported side effects within the central nervous system category of adverse reactions reported with the drug.

Q: Can people with liver disease use Hibiotic?

A: The medicine is strictly contraindicated (prohibited) for patients with a previous history of cholestatic jaundice or liver dysfunction specifically linked to its use. For patients with existing liver disease, regulatory documents advise caution and clinical monitoring.

Q: Can taking too much Hibiotic be dangerous?

A: Regulatory documents indicate that taking more than the prescribed amount may lead to adverse events, and in the event of a suspected overdose, advise seeking immediate medical attention. Overdose symptoms may involve gastrointestinal effects and changes to fluid and electrolyte balance.

Q: Is it true that Hibiotic affects your sleep?

A: Insomnia, which refers to difficulty falling or staying asleep, is listed among the less common side effects reported in the clinical experience with this drug, according to regulatory labels.

Q: Is there a generic version of Hibiotic available?

A: Yes, the combination of Amoxicillin and Clavulanate Potassium, which is the formulation in Hibiotic, is widely available in generic form from various manufacturers.

How should Hibiotic be stored and disposed of?

Proper storage and disposal of Hibiotic are strictly defined by regulatory guidelines, differing based on the medication’s form.

Formulation Required Storage Condition Stability/Handling Rules
Oral Tablets Store at room temperature (20 C to 25 C) [FDA]. Keep tightly closed, away from excess heat and moisture [MedlinePlus].
Oral Suspension (Reconstituted) Must be stored under refrigeration (2 C to 8 C) [SmPC]. Do not freeze; must be discarded after 10 days of mixing [FDA].

All forms of this medicine must be kept out of the sight and reach of children, with safety caps securely locked. The official disposal protocol mandates using a drug take-back program. The product must not be flushed down the toilet or disposed of in the sink, as it is not on the FDA's flush list. If a take-back is unavailable, mix the medicine with an undesirable substance, seal it, and place it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hibiotic found in:

A-Z Index: